{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031615","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.922703+00:00","generated_at":"2026-06-08T05:14:58.611621+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avenue Therapeutics reports Q3 net income of $0.5M; cash low, raises $5M","bullets":["Net income $0.5M ($0.06 per share) vs net loss $0.7M in Q3 2022; R&D $0.9M, G&A $1.2M.","Cash $0.2M at Sep 30, 2023; completed $5M public equity offering in Nov 2023.","AJ201 Phase 1b/2a enrollment on track; topline data expected Q2 2024.","BAER-101 preclinical results accepted for AES meeting; IV tramadol Phase 3 design agreed with FDA.","IV tramadol Phase 3 safety study pending additional financing; aim to start as soon as feasible."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031615","json":"https://secwatch.observer/filing/0001437749-23-031615.json","markdown":"https://secwatch.observer/filing/0001437749-23-031615.md","text":"https://secwatch.observer/filing/0001437749-23-031615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/0001437749-23-031615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/atxi20230822_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:14:58.611621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78c05706e789a34e29b5c06872b680f499e79cbf","claim":"AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share, EPS $0.06 per share.","evidence_excerpt":"On November 13, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/0001437749-23-031615-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share"},{"label":"EPS","value":"$0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}